• Xin Lin, Yuanhao Yang, Valery Fuh-Ngwa, Xianyong Yin, Steve Simpson-Yap, Ingrid van der Mei, Simon A Broadley, Anne-Louise Ponsonby, Ausimmune/ AusLong Investigators Group, Kathryn P Burdon, Bruce V Taylor, and Yuan Zhou.
• Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.
• J. Neurol. Neurosurg. Psychiatr. 2023 Jul 1; 94 (7): 526531526-531.

BackgroundThere are currently no specific biomarkers for multiple sclerosis (MS). Identifying robust biomarkers for MS is crucial to improve disease diagnosis and management.MethodsThis study first used six Mendelian randomisation methods to assess causal relationship of 174 metabolites with MS, incorporating data from European-ancestry metabolomics (n=8569-86 507) and MS (n=14 802 MS cases, 26 703 controls) genomewide association studies. Genetic scores for identified causal metabolite(s) were then computed to predict MS disability progression in an independent longitudinal cohort (AusLong study) of 203 MS cases with up to 15-year follow-up.ResultsWe found a novel genetic causal effect of serine on MS onset (OR=1.67, 95% CI 1.51 to 1.84, p=1.73×10-20), such that individuals whose serine level is 1 SD above the population mean will have 1.67 times the risk of developing MS. This is robust across all sensitivity methods (OR ranges from 1.49 to 1.67). In an independent longitudinal MS cohort, we then constructed time-dynamic and time-fixed genetic scores based on serine genetic instrument single-nucleotide polymorphisms, where higher scores for raised serum serine level were associated with increased risk of disability worsening, especially in the time-dynamic model (RR=1.25, 95% CI 1.10 to 1.42, p=7.52×10-4).ConclusionsThese findings support investigating serine as an important candidate biomarker for MS onset and disability progression.© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

10 keywords...

hide…